• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates
Home » Silk Road Medical issues voluntary recall of Enroute transcarotid stent system

Silk Road Medical issues voluntary recall of Enroute transcarotid stent system

January 25, 2021 By Sean Whooley

Silk Road Medical (NSDQ:SILK) announced today that it is voluntarily recalling additional lots of its Enroute transcarotid stent system.

Enroute, which is manufactured by Cardinal Health (NYSE:CAH) subsidiary Cordis, has received a total of six product complaints between September 2020 and January 2021 involving an issue in which a tip detaches from the stent delivery system.

Additionally, test results from lots manufactured in the same time frame as those subject to the recall contributed to the decision to recall an added 48 lots with approximately 1,800 units of the system. The initial recall of five lots was initiated on Jan. 13, with the sixth complaint leading to a total of 53 lots comprising approximately 2,100 units.

The recalled units were manufactured between October 2019 and July 2020. The recall is limited to 6French crossing profile stent systems (9mm-10mm stent diameter sizes), while testing has determined that the 5French crossing profile systems (5mm-8mm stent diameter sizes) are unaffected.

Silk Road Medical has not received reports of either deaths or serious injuries, although the company acknowledged in a news release that such events could occur due to the failure mode associated with the recall.

The company said it is working to replace customer inventory with units oustide of the recalled lots, while it believes Cordis is taking steps to ensure product safety and minimal supply disruption. In collaboration with Cordis and in consultation with the FDA, Silk Road is continuing its investigation into the matter, with plans to address the recall during its fourth-quarter earnings call.

Filed Under: Blood Management, Featured, Food & Drug Administration (FDA), Recalls, Regulatory/Compliance, Vascular Tagged With: Cardinal Health, Cordis Corp., Silk Road Medical Inc.

In case you missed it

  • DTW Podcast: Can AI, advanced imaging and robotics “democratize” surgery?
  • First OTC molecular test for COVID-19 gains FDA nod
  • Private equity firm GTCR forms Epselon Global to acquire healthcare businesses
  • Former Abbott sales director’s age discrimination suit can proceed
  • Second Sight gains FDA nod for retinal system that may never be produced
  • Abbott wins EUA for COVID-19, flu, RSV combo assay
  • Colfax to split to create new orthopedic device giant
  • Iridex, Topcon seal eye care deal
  • SmileDirectClub dips on missed Q4 projections
  • MedAlliance nabs FDA breakthrough nod for drug-eluting coronary balloon
  • Medtronic launches DCB for dialysis patients in Japan
  • Acuitive Technologies gains FDA nod for ligament reconstruction devices
  • Alphatec posts mixed-bag Q4 results
  • Senseonics sinks on mixed bag Q4, massive bottom-line slide
  • Asensus Surgical finalizes name change from TransEnterix, debuts NYSE ticker
  • Organ-chips could streamline drug development, but hurdles remain
  • Ivermectin not supported for mild COVID-19, study says

RSS From Medical Design & Outsourcing

  • First OTC molecular test for COVID-19 gains FDA nod
    The FDA today issued its first emergency use authorization for a molecular COVID-19 diagnostic test for at-home use without a prescription. The Cue Health COVID-19 Test for Home and Over The Counter (OTC) use is a molecular nucleic acid amplification test designed to detect genetic material from the SARS-CoV-2 virus in the nostrils. The authorized… […]
  • A wearable jaundice monitor for newborns?
    Researchers in Japan say they have developed the first wearable device to precisely monitor jaundice, a yellowing of the skin caused by elevated bilirubin levels in the blood that can cause severe medical conditions — even death — in newborns. Jaundice can be treated easily by irradiating the infant with blue light that breaks bilirubin… […]
  • Plastikos to double size of medical manufacturing operation
    Plastikos announced today that the second phase of construction on its Plastikos Medical plant will begin this month. The Erie, Pa.-based company completed the first building in its medical business in 2019 and has added 10 medical injection molding machines since then. The second building will more than double the size of the current ISO-7 cleanroom… […]
  • Paxxus sealant updated for EU-MDR
    Paxxus announced this week that its Chameleon color-changing package seal indicator technology now works with uncoated Tyvek used to package medical devices. Addison, Ill.-based Paxxus said it updated the technology in advance of a new packaging regulation set to go into effect in the EU in May. Chameleon now shows a vivid color-seal indicator when… […]
  • Medtronic hiring Walmart exec to run its supply chain
    Medtronic (NYSE:MDT) CEO Geoff Martha announced that the company is appointing Greg Smith as EVP of global operations and supply chain. In a LinkedIn post today, Martha wrote: “I’m pleased to share that Greg Smith, Executive Vice President of U.S. Supply Chain for Walmart, is joining Medtronic on April 5 as Executive Vice President of… […]
  • Philips and Disney want to make MRIs easier for children: Here’s how
    Royal Philips (NYSE:PHG) announced today that it is teaming up with Disney to test the effects of custom-made animation to create a relaxing atmosphere for young patients. Amsterdam-based Philips will collaborate with The Walt Disney Company EMEA to see whether the animation, including specially-made Disney stories within Philips’ Ambient Experience, creates a relaxing atmosphere to improve… […]
  • Origami Surgical gains FDA clearance for robotic suturing devices
    Origami Surgical today announced that the FDA has granted 510(k) clearance for three new types of sutures for its StitchKit robotic surgery platform. The company describes StitchKit as a patented suture delivery and retrieval system designed so sutures are efficiently inserted and needles are safely removed from the surgical field. StitchKit also allows the robotic… […]
  • NAMSA acquires American Preclinical Services
    Contract research organization NAMSA today announced its acquisition of Minneapolis-based American Preclinical Services (APS). This purchase follows NAMSA’s acquisition of New York-based Syntactx, a clinical research services CRO, in January. The acquisition will provide NAMSA customers with a broader range of laboratory models and analysis tools, including innovative surgical instrumentation and several state-of-the-art catheterization labs,… […]
  • 5 reasons Medtronic’s CEO is optimistic about the future
    Nearly a year after Geoff Martha took over the corner office at Medtronic, the world’s largest medical device company is transforming. In a recent interview with our DeviceTalks Weekly podcast, Martha detailed Medtronic‘s major reorganization, its shift in corporate culture and more. Martha was also highly pleased about Medtronic’s recent Q3 earnings results. Here are… […]
  • Medtronic is changing a lot: Here’s what you need to know
    CEO Geoff Martha says Medtronic‘s ongoing corporate restructuring will position the company to compete better with medical device rivals, freeing the front-line forces from earlier entanglements. But the change will also create new opportunities for Medtronic employees at the company and elsewhere. In a far-ranging interview with the DeviceTalks Weekly podcast, Martha reviewed the company’s… […]
  • Pharma’s been slow to adopt Industry 4.0 — but that could change
    The pharma industry has been relatively slow to embrace concepts such as Industry 4.0, but COVID-19 is serving as a catalyst for sweeping changes within the industry. The philosophy has roots in a German framework that prioritizes digitization to drive manufacturing efficiency, promising that cyber-physical systems will usher in the next industrial revolution. The Industry… […]

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS